Trial Profile
Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis [EXTENSION OF 700013650]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2013
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Bayer
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 01 Mar 2013 New trial record